LONDON, January 20, 2015 /PRNewswire/ --
Investor-Edge has initiated coverage on the following equities: Novavax Inc. (NASDAQ: NVAX), Isis Pharmaceuticals Inc. (NASDAQ: ISIS), OPKO Health Inc. (NYSE: OPK), Nanosphere Inc. (NASDAQ: NSPH), and NewLink Genetics Corporation (NASDAQ: NLNK). Free research reports can be accessed at the links given below. On Friday, January 16, 2015, the NASDAQ Composite ended at 4,634.38, up 1.39%, the Dow Jones Industrial Average advanced 1.10%, to finish the day at 17,511.57, and the S&P 500 closed at 2,019.42, up 1.34%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 814.62, up 1.92%, with the index also advancing 15.08% in the previous three months. Register for your complimentary reports at the links given below.
On Friday, shares in Novavax Inc. fluctuated between $6.06 and $6.92 before ending the session 9.84% higher at $6.81. The stock reported a trading volume of 40.46 million shares, much above its three months average volume of 4.60 million shares. Novavax Inc.'s shares have advanced 15.23% in the last one month, 39.55% in the previous three months and 11.09% in the last one year. The company's stock is trading above its 50-day and 200-day moving averages of $5.60 and $4.79, respectively. Moreover, shares of Novavax Inc. have a Relative Strength Index (RSI) of 66.45. Sign up and read the free notes on NVAX at:
Isis Pharmaceuticals Inc.'s stock edged 0.77% higher, to close the day at $69.37. The stock recorded a trading volume of 4.92 million shares, above its three months average volume of 3.07 million shares. The stock oscillated between $66.80 and $69.49 during the session. Over the last one month and over the past three months, Isis Pharmaceuticals Inc.'s shares have rallied 20.69% and 73.99%, respectively. Further, the stock has surged 47.16% in the previous one year. The company's stock is trading above its 50-day and 200-day moving averages. The stock's 50-day moving average of $57.88 is above its 200-day moving average of $40.44. Additionally, Isis Pharmaceuticals Inc.'s stock has an RSI of 59.63. The complimentary notes on ISIS can be downloaded as in PDF format at:
On Friday, shares in OPKO Health Inc. recorded a trading volume of 2.75 million shares, higher than its three months average volume of 2.49 million shares. The stock ended the day at $10.02, which was 0.50% above its previous day's closing of $9.97, and registered an intraday range of $9.91 and $10.13. OPKO Health Inc.'s shares have surged 7.40% in the last one month, 21.45% in the previous three months and 14.91% in the past one year. The company's stock is trading above its 50-day and 200-day moving averages of $9.00 and $8.76, respectively. Furthermore, shares of OPKO Health Inc. have an RSI of 60.57. Register for free on Investor-Edge and access the latest research on OPK at:
Nanosphere Inc.'s stock lost 3.28%, to close Friday's session at $0.33, after oscillating between $0.31 and $0.35. The stock recorded a trading volume of 0.79 million shares, much below its three months average volume of 1.96 million shares. Over the previous three trading sessions and the last one month, Nanosphere Inc.'s shares have declined 4.41% and 6.84%, respectively. Additionally, the stock has plummeted 87.51% in the last one year. The company's stock is trading below its 50-day and 200-day moving averages. The stock's 200-day moving average of $0.99 is above its 50-day moving average of $0.39. Further, Nanosphere Inc.'s stock has an RSI of 34.28. The complete research on NSPH is available for free at:
NewLink Genetics Corp.'s stock finished Friday's session 2.47% higher at $38.63. A total of 0.72 million shares were traded, which was below its three months average volume of 1.01 million shares. The stock moved between $36.64 and $38.95 during the session. Over the last one month and the previous three months, NewLink Genetics Corp.'s shares have surged 11.87% and 31.62%, respectively. Additionally, the stock has gained 21.02% in the past one year. The company's shares are trading above their 50-day and 200-day moving averages. Moreover, the stock's 50-day moving average of $36.65 is greater than its 200-day moving average of $27.43. NewLink Genetics Corp.'s stock has an RSI of 50.33. Free in depth research on NLNK is available at:
At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.investor-edge.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.